The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

October 9, 2019 • By Caroline Humer

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1

You Might Also Like
  • Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
  • Major Drugmakers Push Back in U.S. Price Debate
  • Trump Administration to Appeal Ruling Blocking Price Disclosure for Drug Ads

The price hikes were more than twice the rate of medical inflation and not supported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

It was the first such annual report by the Boston-based research group, which assesses the cost-effectiveness of drugs.2

Other top treatments by spending that were called out in the report were Pfizer Inc.’s pain drug Lyrica, Gilead Sciences Inc.’s HIV drug Truvada, Amgen Inc.’s white blood cell booster Neulasta, Eli Lilly & Co.’s erectile dysfunction drug Cialis and Biogen Inc.’s multiple sclerosis treatment Tecfidera.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

U.S. drug prices are tough to pin down. Companies may provide list prices, but they also negotiate discounts and after-market rebates with purchasers and their representatives such as pharmacy benefit managers, health insurers, employers and government and state health coverage programs.

Drugmakers have been under increasing political scrutiny to lower costs to consumers and have responded by limiting annual list price hikes to under 10% in many cases.

ICER evaluated the pricing in partnerships with SSR Health Inc., a research firm, which calculated the increases excluding discounts and after-market rebates.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

AbbVie spokeswoman Adelle Infante said ICER’s data on its net pricing is inaccurate and called into question the group’s methodology.

Roche spokeswoman Emmy Wang said in pricing drugs, the company strived for the right balance between patient access and investing for breakthroughs in medicine.

Gilead, Biogen, Pfizer and Eli Lilly questioned ICER’s analysis, methodology and conclusions, with Lilly spokesman Mark Taylor noting generic versions of Cialis were now available for up to 90% less than the retail price.

Amgen did not have an immediate comment.

ICER acknowledged it was difficult to determine the actual increase in spending on the drugs, but said it was confident that the seven drugs cost a lot more.

Pricing drugs based on new benefits could help slow cost hikes, ICER Chief Medical Officer David Rind said.

“If manufacturers weren’t raising prices if they haven’t shown a new important benefit, I think that would help,” he said.

Celgene’s multiple myeloma drug Revlimid and Gilead’s HIV treatment Genovya were also large contributors to spending, but were excluded from the list because of their clinical advancements, ICER said.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: adalimumab, drug prices, rituximab

You Might Also Like:
  • Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
  • Major Drugmakers Push Back in U.S. Price Debate
  • Trump Administration to Appeal Ruling Blocking Price Disclosure for Drug Ads
  • Two U.S. Lawmakers Probe Marathon over $89,000 Drug Price

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)